Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 for reducing hospital stay after on-pump CABG surgery
2025-525053-39-00Phase 3Authorised
- Sponsor
- EBI
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing EA-230 with Placebo (2 arms). Primary endpoint: Time to hospital discharge eligibility. Planned start Oct 2026; status: authorised.
02
Drugs
EA-230
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-525053-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525053-39-00.